united therapeutics glp-1 receptor agonist agonists and next-generation metabolic hormone therapies in chronic kidney disease Understanding GLP-1 receptor agonists and
Description
consumers (Amin et al., 2023)
Both overeating and excessive drinking are mediated by the mesolimbic dopamine pathway the brains reward circuit
Patients are typically instructed by their clinician or dispensing pharmacy on how to prepare and administer each dose
Your AID algorithm will need time to adapt to the new patterns, and your basal and bolus settings will likely need recalibration
10.2174/1570159X14666160219131357 [DOI] [PMC free article] [PubMed] [Google Scholar] Slyepchenko A., Maes M., Kohler C
2025;41(5):e70058
